Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.

ABSTRACT: Nucleotide excision repair (NER) plays a vital role in platinum-induced DNA damage during chemotherapy. We hypothesize that regulatory single nucleotide polymorphisms (rSNPs) of the core NER genes modulate clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy (PBS). We investigated associations of 25 rSNPs in eight NER genes with progression free survival (PFS) and overall survival (OS) in 710 NSCLC patients. We found that ERCC1 rs3212924 AG/GG and XPC rs2229090 GC/CC genotypes were associated with patients' PFS (HR_adj = 1.21, 95% CI = 1.03-1.43, P _adj = 0.021 for ERCC1 and HR_adj = 0.80, 95% CI = 0.68-0.94, P _adj = 0.007 for XPC), compared with the AA and GG genotypes, respectively.

SUBMITTER: Zhang R 

PROVIDER: S-EPMC5587538 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature